RU2010141333A - Новая доза и препаративная форма - Google Patents
Новая доза и препаративная форма Download PDFInfo
- Publication number
- RU2010141333A RU2010141333A RU2010141333/15A RU2010141333A RU2010141333A RU 2010141333 A RU2010141333 A RU 2010141333A RU 2010141333/15 A RU2010141333/15 A RU 2010141333/15A RU 2010141333 A RU2010141333 A RU 2010141333A RU 2010141333 A RU2010141333 A RU 2010141333A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- aclidinium
- composition according
- aklidinium
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 24
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 claims abstract 19
- 229940019903 aclidinium Drugs 0.000 claims abstract 13
- 239000000843 powder Substances 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 229960005012 aclidinium bromide Drugs 0.000 claims abstract 6
- 239000002245 particle Substances 0.000 claims abstract 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims abstract 5
- 238000009472 formulation Methods 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims abstract 5
- 239000003937 drug carrier Substances 0.000 claims abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 4
- 239000008101 lactose Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 10
- 239000013543 active substance Substances 0.000 claims 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000000241 respiratory effect Effects 0.000 claims 3
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical group OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical group C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- 229960000193 formoterol fumarate Drugs 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 229960004017 salmeterol Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Фармацевтическая композиция для ингаляции, содержащая аклидиний в форме сухого порошка фармацевтически приемлемой соли в смеси с фармацевтически приемлемым носителем в форме сухого порошка, которая содержит отмеренную номинальную дозу аклидиния, эквивалентную примерно 400 мкг аклидиния бромида. ! 2. Фармацевтическая композиция по п.1 в виде однодозовой препаративной формы в виде сухого порошка, содержащей одну отмеренную номинальную дозу аклидиния, эквивалентную примерно 400 мкг аклидиния бромида. ! 3. Фармацевтическая композиция по п.1 в виде мультидозовой препаративной формы в виде сухого порошка, предназначенная для введения с помощью мультидозового ингаляторного устройства для сухого порошка, которое откалибровано для обеспечения введения отмеренной номинальной дозы аклидиния, эквивалентной примерно 400 мкг аклидиния бромида. ! 4. Фармацевтическая композиция по одному из предыдущих пунктов, в которой фармацевтически приемлемая соль аклидиния представляет собой аклидиния бромид. ! 5. Фармацевтическая композиция по п.1, в которой фармацевтически приемлемый носитель представляет собой частицы лактозы. ! 6. Фармацевтическая композиция по п.1, в которой массовое соотношение аклидиния и носителя составляет от 1:25 до 1:75. ! 7. Фармацевтическая композиция по п.6, в которой массовое соотношение аклидиния и носителя составляет от 1:50 до 1:75. ! 8. Фармацевтическая композиция по п.1, в которой средний диаметр частиц аклидиния составляет 2-5 мкм. ! 9. Фармацевтическая композиция по п.1, в которой частицы носителя характеризуются величиной dl0, составляющей 90-160 мкм, величиной d50, составляющей 170-270 мкм, и величиной d90, составляю�
Claims (26)
1. Фармацевтическая композиция для ингаляции, содержащая аклидиний в форме сухого порошка фармацевтически приемлемой соли в смеси с фармацевтически приемлемым носителем в форме сухого порошка, которая содержит отмеренную номинальную дозу аклидиния, эквивалентную примерно 400 мкг аклидиния бромида.
2. Фармацевтическая композиция по п.1 в виде однодозовой препаративной формы в виде сухого порошка, содержащей одну отмеренную номинальную дозу аклидиния, эквивалентную примерно 400 мкг аклидиния бромида.
3. Фармацевтическая композиция по п.1 в виде мультидозовой препаративной формы в виде сухого порошка, предназначенная для введения с помощью мультидозового ингаляторного устройства для сухого порошка, которое откалибровано для обеспечения введения отмеренной номинальной дозы аклидиния, эквивалентной примерно 400 мкг аклидиния бромида.
4. Фармацевтическая композиция по одному из предыдущих пунктов, в которой фармацевтически приемлемая соль аклидиния представляет собой аклидиния бромид.
5. Фармацевтическая композиция по п.1, в которой фармацевтически приемлемый носитель представляет собой частицы лактозы.
6. Фармацевтическая композиция по п.1, в которой массовое соотношение аклидиния и носителя составляет от 1:25 до 1:75.
7. Фармацевтическая композиция по п.6, в которой массовое соотношение аклидиния и носителя составляет от 1:50 до 1:75.
8. Фармацевтическая композиция по п.1, в которой средний диаметр частиц аклидиния составляет 2-5 мкм.
9. Фармацевтическая композиция по п.1, в которой частицы носителя характеризуются величиной dl0, составляющей 90-160 мкм, величиной d50, составляющей 170-270 мкм, и величиной d90, составляющей 290-400 мкм.
10. Фармацевтическая композиция по п.1, которая содержит также в эффективном количестве одно или несколько дополнительных действующих веществ, выбранных из β2-агонистов, ингибиторов PDE IV и кортикостероидов.
11. Фармацевтическая композиция по п.10, в которой дополнительное действующее вещество выбрано из формотерола, салметерола, будесонида и мометазона в свободной форме или в форме фармацевтически приемлемой соли.
12. Фармацевтическая композиция по п.11, в которой дополнительное действующее вещество представляет собой формотерола фумарат в количестве, составляющем примерно 5-25 мкг на дозу.
13. Фармацевтическая композиция по п.11, в которой дополнительное действующее вещество представляет собой мометазона фуроат в количестве, составляющем примерно 100-900 мкг на отмеренную номинальную дозу.
14. Способ лечения респираторного состояния, выбранного из астмы и хронического обструктивного заболевания легких, у пациента, который нуждается в таком лечении, заключающийся в том, что вводят ежедневно аклидиний в количестве, составляющем одну отмеренную номинальную дозу, которая эквивалентна примерно 400 мкг аклидиния бромида.
15. Способ лечения респираторного состояния, выбранного из астмы и хронического обструктивного заболевания легких, у пациента, нуждающегося в таком лечении, который заключается в том, что вводят дважды в день аклидиний в количестве, составляющем отмеренную номинальную дозу, которая эквивалентна примерно 400 мкг аклидиния бромида.
16. Способ по п.14 или 15, заключающийся в том, что вводят фармацевтическую композицию по одному из пп.1-13.
17. Способ по п.14, в котором дополнительно вводят в эффективном количестве одно или несколько дополнительных действующих веществ, выбранных из β2-агонистов, ингибиторов PDE IV и кортикостероидов.
18. Способ по п.17, в котором дополнительное действующее вещество выбирают из формотерола, салметерола, будесонида и мометазона в свободной форме или в форме фармацевтически приемлемой соли.
19. Способ по п.18, в котором дополнительное действующее вещество представляет собой формотерола фумарат в количестве, составляющем примерно 5-25 мкг на отмеренную номинальную дозу.
20. Способ по п.18, в котором дополнительное действующее вещество представляет собой мометазона фуроат в количестве, составляющем примерно 100-900 мкг на отмеренную номинальную дозу.
21. Применение аклидиния в свободной форме или в форме фармацевтически приемлемой соли для приготовления лекарственного средства, предназначенного для введения согласно способу по одному из пп.14-20.
22. Применение аклидиния в свободной форме или в форме фармацевтически приемлемой соли для приготовления фармацевтической композиции по одному из пп.1-13.
23. Аклидиний в свободной форме или в форме фармацевтически приемлемой соли, предназначенный для применения согласно одному из способов по пп.14-20.
24. Препаративная форма по п.1, предназначенная для применения согласно одному из способов по пп.14-20.
25. Препаративная форма по п.1, предназначенная для лечения респираторного состояния, выбранного из астмы и хронического обструктивного заболевания легких.
26. Мультидозовое ингаляторное устройство для сухого порошка, откалиброванное для обеспечения введения после его задействования отмеренной номинальной дозы аклидиния, эквивалентной примерно 400 мкг аклидиния бромида.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08382010A EP2100599A1 (en) | 2008-03-13 | 2008-03-13 | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP08382010.0 | 2008-03-13 | ||
| PCT/EP2009/001832 WO2009112274A2 (en) | 2008-03-13 | 2009-03-13 | Novel dosage and formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140674A Division RU2014140674A (ru) | 2008-03-13 | 2014-10-08 | Новая дозировка и препаративная форма |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2010141333A true RU2010141333A (ru) | 2012-04-20 |
| RU2608713C2 RU2608713C2 (ru) | 2017-01-23 |
| RU2608713C3 RU2608713C3 (ru) | 2018-09-10 |
Family
ID=39645012
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141333A RU2608713C3 (ru) | 2008-03-13 | 2009-03-13 | Новая доза и препаративная форма |
| RU2014140674A RU2014140674A (ru) | 2008-03-13 | 2014-10-08 | Новая дозировка и препаративная форма |
| RU2019100425A RU2019100425A (ru) | 2008-03-13 | 2019-01-11 | Новая доза и препаративная форма |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140674A RU2014140674A (ru) | 2008-03-13 | 2014-10-08 | Новая дозировка и препаративная форма |
| RU2019100425A RU2019100425A (ru) | 2008-03-13 | 2019-01-11 | Новая доза и препаративная форма |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20110020412A1 (ru) |
| EP (5) | EP2100599A1 (ru) |
| JP (3) | JP2011513451A (ru) |
| KR (3) | KR20180125055A (ru) |
| CN (2) | CN102083416A (ru) |
| AR (1) | AR070835A1 (ru) |
| AU (1) | AU2009224895B9 (ru) |
| BR (1) | BRPI0905775B1 (ru) |
| CA (1) | CA2716724C (ru) |
| CL (1) | CL2009000602A1 (ru) |
| CO (1) | CO6290636A2 (ru) |
| CY (3) | CY1116926T1 (ru) |
| DK (3) | DK2954891T3 (ru) |
| EC (1) | ECSP10010300A (ru) |
| ES (3) | ES2916831T3 (ru) |
| FI (1) | FI2265257T4 (ru) |
| HR (3) | HRP20220929T3 (ru) |
| HU (3) | HUE059019T2 (ru) |
| IL (3) | IL271132B2 (ru) |
| LT (2) | LT2954889T (ru) |
| ME (1) | ME02286B (ru) |
| MX (2) | MX2010008235A (ru) |
| MY (1) | MY177027A (ru) |
| NZ (1) | NZ585857A (ru) |
| PE (3) | PE20190406A1 (ru) |
| PL (3) | PL2265257T5 (ru) |
| PT (3) | PT2954891T (ru) |
| RS (3) | RS63399B1 (ru) |
| RU (3) | RU2608713C3 (ru) |
| SG (1) | SG188825A1 (ru) |
| SI (3) | SI2954891T1 (ru) |
| TW (1) | TWI439296B (ru) |
| UA (1) | UA101652C2 (ru) |
| UY (1) | UY31687A1 (ru) |
| WO (1) | WO2009112274A2 (ru) |
| ZA (1) | ZA201003900B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) * | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2666465A1 (en) * | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
| WO2014007767A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| WO2014007766A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| PL2931275T3 (pl) * | 2012-12-17 | 2022-09-05 | Almirall S.A. | Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc |
| AU2014261539A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| EP2923702A1 (en) * | 2014-03-28 | 2015-09-30 | Universite De Liege | Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease |
| RU2688191C2 (ru) | 2014-05-12 | 2019-05-21 | ВЕРОНА ФАРМА ПиэЛСи | Новое лечение |
| CZ2015257A3 (cs) * | 2015-04-16 | 2016-10-26 | Zentiva, K.S. | Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu |
| CN107823193B (zh) * | 2017-11-16 | 2021-02-05 | 广州迈达康医药科技有限公司 | 一种阿地溴铵吸入型粉雾剂及其制备方法 |
Family Cites Families (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3091570A (en) | 1960-08-08 | 1963-05-28 | Lakeside Lab Inc | Antidepressant: 3-pyrrolidyl glycolates |
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| FR2414044A1 (fr) | 1978-01-10 | 1979-08-03 | Pharmindustrie | Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments |
| IT7920688U1 (it) | 1979-02-05 | 1980-08-05 | Chiesi Paolo | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore |
| IT1116047B (it) | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| FR2539135B1 (fr) | 1983-01-11 | 1986-02-28 | Essilor Int | Hydrogels de polyurethane et procede de fabrication |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| US4675326A (en) | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
| US4855290A (en) | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| GB8718345D0 (en) | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
| US4843074A (en) | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| US5507281A (en) | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| DE69132735T2 (de) | 1990-09-06 | 2002-05-29 | Pfizer Inc., New York | Anti-muscarin bronchodilatoren |
| US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| ATE209938T1 (de) | 1990-09-26 | 2001-12-15 | Pharmachemie Bv | Wirbelkammer-pulverinhalator |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
| GB9119705D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic compounds |
| US5865834A (en) | 1991-12-13 | 1999-02-02 | Mcguire; David A. | Coring reamer |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| WO1994013263A1 (en) | 1992-12-09 | 1994-06-23 | Jager Paul D | Stabilized medicinal aerosol solution formulations |
| UA27961C2 (ru) | 1992-12-18 | 2000-10-16 | Шерінг Корпорейшн | Ингалятор для порошковых лекарств |
| EP0747355A4 (en) | 1994-02-10 | 1997-04-09 | Yamanouchi Pharma Co Ltd | NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM |
| GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
| US5569447A (en) | 1994-04-19 | 1996-10-29 | The United States Of America Represented By The Secretary Department Of Health And Human Services | Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives |
| JP3548933B2 (ja) | 1994-07-29 | 2004-08-04 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 架橋結合された粘弾性高分子材料に硬化可能なアクリル系シロップ |
| GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| EP1908488A3 (en) | 1995-04-14 | 2008-04-16 | SmithKline Beecham Corporation | Metered dose inhaler for salmeterol |
| AU719449B2 (en) | 1995-06-21 | 2000-05-11 | Astrazeneca Ab | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
| AU6392496A (en) | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
| DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
| US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| US6423298B2 (en) | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| EP1087750B1 (en) | 1998-06-18 | 2003-11-12 | Boehringer Ingelheim Pharmaceuticals Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
| EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| US5962505A (en) | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
| DE19847968A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
| GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| DE19912434B4 (de) * | 1999-03-19 | 2013-10-24 | Roche Diagnostics Gmbh | Infusionsgerät, Kathetereinrichtung und Katheterkopf |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
| GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| FR2803378B1 (fr) | 1999-12-29 | 2004-03-19 | Valeo Climatisation | Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile |
| CA2398199A1 (en) | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | Novel therapeutic agents that use a .beta.3 agonist |
| WO2001057025A1 (en) | 2000-01-31 | 2001-08-09 | Pfizer Products Inc. | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| CA2404226A1 (en) | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
| GB0008485D0 (en) | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| BR0015884A (pt) | 2000-05-22 | 2003-07-08 | Chiesi Farma Spa | Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| AR029984A1 (es) | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
| AU2001285430A1 (en) | 2000-08-10 | 2002-02-18 | Eharmony.Com, Inc | Method and system for identifying people who care likely to have a succesful relationship |
| US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| US6852728B2 (en) | 2000-10-14 | 2005-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
| AU2002210575A1 (en) * | 2000-10-31 | 2002-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel medicament compositions based on anticholinergics and corticosteroids |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| US6620438B2 (en) | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
| US6608054B2 (en) * | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
| US20020122773A1 (en) * | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US20020151541A1 (en) * | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
| US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
| US20020193392A1 (en) | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
| DE10056104A1 (de) | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
| US20100310477A1 (en) | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
| KR100869722B1 (ko) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용 |
| NZ526674A (en) | 2000-12-28 | 2005-03-24 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
| US20020189610A1 (en) | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
| DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
| DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
| US20020179087A1 (en) | 2001-02-01 | 2002-12-05 | Karl-Heinz Bozung | Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030216329A1 (en) | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
| CZ20033150A3 (cs) | 2001-05-25 | 2004-06-16 | Pfizer Inc. | Inhibitor PDE4 a anticholinergní činidlo v kombinaci pro léčbu obstruktivních chorob dýchacích cest |
| MXPA03010791A (es) | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. |
| GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US6680345B2 (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol |
| US6919325B2 (en) | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
| CA2459493C (en) | 2001-09-14 | 2011-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pharmaceutical compositions for inhalation |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US6790856B2 (en) | 2002-01-31 | 2004-09-14 | Boehringer Ingelheim Pharma Kg | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
| GB0202635D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| KR100947409B1 (ko) | 2002-03-01 | 2010-03-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 포모테롤 초미세 조성물 |
| US6756508B2 (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
| DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| DE10216333A1 (de) | 2002-04-13 | 2003-10-30 | Boehringer Ingelheim Pharma | Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7094788B2 (en) | 2002-04-13 | 2006-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| NZ536555A (en) | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| US20040058950A1 (en) | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| AU2003289898A1 (en) | 2002-11-27 | 2004-06-18 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| DE10307759B3 (de) | 2003-02-19 | 2004-11-18 | Schering Ag | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| US20040184995A1 (en) | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
| SI1610787T1 (sl) | 2003-03-28 | 2008-06-30 | Nycomed Gmbh | Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni |
| US20060189642A1 (en) | 2003-03-28 | 2006-08-24 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| RU2361586C2 (ru) * | 2003-07-29 | 2009-07-20 | Берингер Ингельхайм Интернациональ Гмбх | Комбинация из антихолинергического средства и стероида и ее применение для лечения заболеваний дыхательных путей путем ингаляции |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| PT1651270E (pt) * | 2003-07-29 | 2007-04-30 | Boehringer Ingelheim Int | Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico |
| US20050026887A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
| US20050026886A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
| CA2534125A1 (en) | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| CA2534120C (en) | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PT1713473E (pt) | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| WO2005074982A2 (en) | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| DE602005007708D1 (de) | 2004-02-06 | 2008-08-07 | Meda Pharma Gmbh & Co Kg | Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen |
| ES2239546B1 (es) | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
| DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| SI1765404T1 (sl) * | 2004-05-31 | 2009-04-30 | Almirall Lab | Kombinacije, ki obsegajo antimuskarinska sredstva in beta-adrenergične agoniste |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| JP2010519195A (ja) | 2007-02-19 | 2010-06-03 | シプラ・リミテッド | 薬学的組成物 |
| KR20090114401A (ko) | 2007-02-21 | 2009-11-03 | 알미랄 에스.에이. | 신규 방법 |
| EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2666465A1 (en) † | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
| PL2931275T3 (pl) | 2012-12-17 | 2022-09-05 | Almirall S.A. | Aklidyna do zastosowania w zwiększaniu aktywności fizycznej w codziennym życiu u pacjenta z przewlekłą obturacyjną chorobą płuc |
| WO2014096553A1 (en) | 2012-12-21 | 2014-06-26 | Intellipocket Oy | Generating a customized application |
-
2008
- 2008-03-13 EP EP08382010A patent/EP2100599A1/en not_active Withdrawn
-
2009
- 2009-03-02 UY UY031687A patent/UY31687A1/es not_active Application Discontinuation
- 2009-03-06 TW TW098107410A patent/TWI439296B/zh active
- 2009-03-11 PE PE2018001507A patent/PE20190406A1/es unknown
- 2009-03-11 PE PE2009000357A patent/PE20091672A1/es not_active Application Discontinuation
- 2009-03-11 PE PE2014000415A patent/PE20141036A1/es not_active Application Discontinuation
- 2009-03-12 CL CL2009000602A patent/CL2009000602A1/es unknown
- 2009-03-12 AR ARP090100878A patent/AR070835A1/es unknown
- 2009-03-13 RS RS20220675A patent/RS63399B1/sr unknown
- 2009-03-13 SI SI200932164T patent/SI2954891T1/sl unknown
- 2009-03-13 ES ES15173011T patent/ES2916831T3/es active Active
- 2009-03-13 EP EP09719213.2A patent/EP2265257B2/en active Active
- 2009-03-13 PL PL09719213.2T patent/PL2265257T5/pl unknown
- 2009-03-13 NZ NZ585857A patent/NZ585857A/xx unknown
- 2009-03-13 JP JP2010550092A patent/JP2011513451A/ja not_active Withdrawn
- 2009-03-13 HR HRP20220929TT patent/HRP20220929T3/hr unknown
- 2009-03-13 LT LTEP15173000.9T patent/LT2954889T/lt unknown
- 2009-03-13 PL PL15173000.9T patent/PL2954889T3/pl unknown
- 2009-03-13 KR KR1020187033056A patent/KR20180125055A/ko not_active Ceased
- 2009-03-13 DK DK15173011.6T patent/DK2954891T3/da active
- 2009-03-13 LT LTEP15173011.6T patent/LT2954891T/lt unknown
- 2009-03-13 EP EP15173009.0A patent/EP2954890A1/en not_active Withdrawn
- 2009-03-13 SI SI200931274T patent/SI2265257T2/sl unknown
- 2009-03-13 MX MX2010008235A patent/MX2010008235A/es active IP Right Grant
- 2009-03-13 SI SI200932165T patent/SI2954889T1/sl unknown
- 2009-03-13 CN CN2009801028707A patent/CN102083416A/zh active Pending
- 2009-03-13 HU HUE15173000A patent/HUE059019T2/hu unknown
- 2009-03-13 HU HUE15173011A patent/HUE059020T2/hu unknown
- 2009-03-13 PT PT151730116T patent/PT2954891T/pt unknown
- 2009-03-13 US US12/921,921 patent/US20110020412A1/en not_active Abandoned
- 2009-03-13 ES ES15173000T patent/ES2914674T3/es active Active
- 2009-03-13 HR HRP20151214TT patent/HRP20151214T4/hr unknown
- 2009-03-13 RU RU2010141333A patent/RU2608713C3/ru active Protection Beyond IP Right Term
- 2009-03-13 HR HRP20220919TT patent/HRP20220919T3/hr unknown
- 2009-03-13 EP EP15173000.9A patent/EP2954889B1/en active Active
- 2009-03-13 KR KR1020107018743A patent/KR20100126322A/ko not_active Ceased
- 2009-03-13 SG SG2013014659A patent/SG188825A1/en unknown
- 2009-03-13 WO PCT/EP2009/001832 patent/WO2009112274A2/en not_active Ceased
- 2009-03-13 RS RS20150612A patent/RS54241B2/sr unknown
- 2009-03-13 PT PT97192132T patent/PT2265257E/pt unknown
- 2009-03-13 ES ES09719213T patent/ES2551307T5/es active Active
- 2009-03-13 DK DK15173000.9T patent/DK2954889T3/da active
- 2009-03-13 ME MEP-2015-161A patent/ME02286B/me unknown
- 2009-03-13 RS RS20220674A patent/RS63398B1/sr unknown
- 2009-03-13 BR BRPI0905775-7A patent/BRPI0905775B1/pt active IP Right Grant
- 2009-03-13 AU AU2009224895A patent/AU2009224895B9/en active Active
- 2009-03-13 CN CN201410583909.4A patent/CN104473911A/zh active Pending
- 2009-03-13 UA UAA201012043A patent/UA101652C2/ru unknown
- 2009-03-13 CA CA2716724A patent/CA2716724C/en active Active
- 2009-03-13 MY MYPI2010004245A patent/MY177027A/en unknown
- 2009-03-13 FI FIEP09719213.2T patent/FI2265257T4/fi active
- 2009-03-13 IL IL271132A patent/IL271132B2/en unknown
- 2009-03-13 KR KR1020207013179A patent/KR20200054329A/ko not_active Ceased
- 2009-03-13 DK DK09719213.2T patent/DK2265257T4/da active
- 2009-03-13 EP EP15173011.6A patent/EP2954891B1/en active Active
- 2009-03-13 PT PT151730009T patent/PT2954889T/pt unknown
- 2009-03-13 PL PL15173011.6T patent/PL2954891T3/pl unknown
- 2009-03-13 MX MX2015010247A patent/MX368774B/es unknown
- 2009-03-13 HU HUE09719213A patent/HUE027726T2/en unknown
-
2010
- 2010-06-01 ZA ZA2010/03900A patent/ZA201003900B/en unknown
- 2010-06-14 IL IL206354A patent/IL206354A0/en unknown
- 2010-06-23 EC EC2010010300A patent/ECSP10010300A/es unknown
- 2010-09-13 CO CO10112800A patent/CO6290636A2/es not_active Application Discontinuation
-
2012
- 2012-12-03 US US13/692,032 patent/US10085974B2/en active Active
-
2014
- 2014-04-07 JP JP2014078703A patent/JP6170460B2/ja active Active
- 2014-10-08 RU RU2014140674A patent/RU2014140674A/ru unknown
-
2015
- 2015-11-10 CY CY20151101008T patent/CY1116926T1/el unknown
-
2016
- 2016-03-16 JP JP2016052576A patent/JP2016130248A/ja active Pending
- 2016-11-20 IL IL249072A patent/IL249072A0/en unknown
-
2018
- 2018-06-27 US US16/019,855 patent/US11000517B2/en active Active
-
2019
- 2019-01-11 RU RU2019100425A patent/RU2019100425A/ru not_active Application Discontinuation
-
2022
- 2022-07-25 CY CY20221100503T patent/CY1125382T1/el unknown
- 2022-07-25 CY CY20221100502T patent/CY1125381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010141331A (ru) | Новая доза и препаративная форма | |
| RU2010141333A (ru) | Новая доза и препаративная форма | |
| JP2015519356A5 (ru) | ||
| JP2012082229A (ja) | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 | |
| JP2015519394A (ja) | キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法 | |
| JP2021529771A (ja) | クロモリンナトリウムおよびα−ラクトースの粉末製剤 | |
| RU2015143927A (ru) | Деаморфизация высушенных распылением составов посредством смешивания распылением | |
| UA119774C2 (uk) | Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл) | |
| CN107205936A (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| HUE031442T2 (en) | Aclidinium for use in improving the quality of sleep in respiratory patients. | |
| AU2010238641A1 (en) | Agglomerate formulations useful in dry powder inhalers | |
| EP2682099B1 (en) | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | |
| CN107496388B (zh) | 一种含有福莫特罗和噻托铵盐组合物的粉状制剂及其制备方法 | |
| EP2821062A1 (en) | Novel dry powder inhaler formulations | |
| CN104869996A (zh) | 阿地铵的新用途 | |
| RU2494730C1 (ru) | Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения | |
| WO2022146257A1 (en) | A process for the preparation of dry powder compositions for inhalation | |
| WO2021058454A1 (en) | Novel carrier particles for dry powder formulations for inhalation | |
| TW201618759A (zh) | 具有經改善之組合型活性成分之穩定性的吸入型調配物乾粉末 | |
| TW201605432A (zh) | 新穎劑量及調配物 | |
| WO2015060743A1 (ru) | Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения | |
| WO2015065220A1 (ru) | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20180910 |